ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

ASTRO Members Approve Governance, Dues Changes

January 17, 2003

Also in this 8-page issue: David Hohn elected board chairman of the National Comprehensive Cancer Network.

March 26, 2004

DCT Board Okays Recompetitions

June 21, 1985

FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer

December 28, 2012

In Brief: Robert McKenna Named New President Of Society Of Surgical Oncology, Hiram Polk President Elect

May 13, 1983

Bioassay Backlog Reports show Increasing Number Of Equivocal Results; Is The Program A Failure?

September 2, 1977